{
    "clinical_study": {
        "@rank": "161354", 
        "arm_group": [
            {
                "arm_group_label": "ARM A", 
                "arm_group_type": "Experimental", 
                "description": "ABT-450/r/ABT-267 and ABT-333 with ribavirin (RBV) for 24 weeks"
            }, 
            {
                "arm_group_label": "ARM B", 
                "arm_group_type": "Experimental", 
                "description": "ABT-450/r/ABT-267 and ABT-333 administered with ribavirin (RBV) for 24 weeks"
            }, 
            {
                "arm_group_label": "ARM C", 
                "arm_group_type": "Experimental", 
                "description": "ABT-450/r/ABT-267 and ABT-333 for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate chronic Hepatitis C Virus infection."
        }, 
        "brief_title": "A Study to Evaluate Chronic Hepatitis C Infection in Adult Liver Transplant Recipients", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir,\n      ABT-267 (ABT-450/r/ABT-267) and ABT-333 with and without ribavirin in adult liver transplant\n      recipients with hepatitis C virus (HCV) infection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Liver transplantation as a consequence of HCV infection no less than 12 months before\n             screening.\n\n          -  Must have a liver biopsy which shows evidence of fibrosis <= F3 (Metavir scale) and\n             which is obtained within the 6 months prior to the screening period but not less than\n             9 months post transplant or during the Screening Period\n\n          -  Chronic hepatitis C genotype 1 infection.\n\n          -  On an immunosuppressant regimen based on either tacrolimus or cyclosporine where the\n             dose of immunosuppressant has not been increased  at least 2 months before Screening\n             and no new immunosuppressant drugs have been added for at leas 2 months before\n             Screening.\n\n        Exclusion Criteria:\n\n          -  Positive hepatitis B surface antigen and anti-Human Immunodeficiency Virus Antibody.\n\n          -  Use of contraindicated medications within 2 weeks of dosing or 10 half-lives.\n\n          -  Clinically significant abnormalities, other than HCV infection post transplant.\n\n          -  Recent history of drug or alcohol abuse.\n\n          -  Previous use of any investigational or commercially available anti-HCV agent other\n             than interferon (IFN)-based therapy, i.e. conventional (c) IFN and/or pegylated (Peg)\n             IFN, with or without RBV without prior AbbVie physician approval."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01782495", 
            "org_study_id": "M12-999", 
            "secondary_id": "2012-004792-39"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ARM A", 
                    "ARM B", 
                    "ARM C"
                ], 
                "description": "tablet", 
                "intervention_name": "ABT-450/r/ABT-267", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ARM A", 
                    "ARM B", 
                    "ARM C"
                ], 
                "description": "tablet", 
                "intervention_name": "ABT-333", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ARM A", 
                    "ARM B"
                ], 
                "description": "tablet", 
                "intervention_name": "ribavirin (RBV)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Hepatitis", 
            "Hepatitis C Virus", 
            "Hepatitis C Genotype 1", 
            "Interferon-Free", 
            "Liver Transplant"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85054"
                    }, 
                    "name": "Site Reference ID/Investigator# 90539"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "Site Reference ID/Investigator# 90538"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Site Reference ID/Investigator# 90535"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Site Reference ID/Investigator# 90562"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "Site Reference ID/Investigator# 90563"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202-5121"
                    }, 
                    "name": "Site Reference ID/Investigator# 90536"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01805"
                    }, 
                    "name": "Site Reference ID/Investigator# 100055"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Site Reference ID/Investigator# 90533"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75203"
                    }, 
                    "name": "Site Reference ID/Investigator# 90537"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 90537", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Site Reference ID/Investigator# 96250"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 96250", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Camperdown", 
                        "country": "Australia", 
                        "zip": "2050"
                    }, 
                    "name": "Site Reference ID/Investigator# 123975"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123975", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94804"
                    }, 
                    "name": "Site Reference ID/Investigator# 123435"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123435", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08028"
                    }, 
                    "name": "Site Reference ID/Investigator# 90573"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Site Reference ID/Investigator# 123355"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123355", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "Open-label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adult Liver Transplant Recipients With Genotype 1 Hepatitis C Virus (HCV) Infection", 
        "overall_contact": {
            "email": "elizabeth.colon@abbvie.com", 
            "last_name": "Elizabeth  Colon, BA", 
            "phone": "847-938-4572"
        }, 
        "overall_contact_backup": {
            "email": "melissa.cook@abbvie.com", 
            "last_name": "Melissa  Cook, MS", 
            "phone": "847-937-1399"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Eoin  Coakley, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hepatitis C virus ribonucleic acid less than the lower limit of quantification", 
            "measure": "Percentage of subjects with sustained virologic response 12 weeks post-treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after the last actual dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01782495"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hepatitis C virus ribonucleic acid less than the lower limit of quantification", 
                "measure": "Percentage of subjects with sustained virologic response 24 weeks post treatment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks after the last actual dose of study drug"
            }, 
            {
                "description": "Hepatitis C virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification, after HCV RNA less than the lower limit of quantification or HCV RNA greater than or equal to the lower limit of quantification at the end of treatment", 
                "measure": "Percentage of subjects with virologic failure during treatment", 
                "safety_issue": "No", 
                "time_frame": "Treatment Day 1 up to 24 weeks"
            }, 
            {
                "description": "Hepatitis C Virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification between the end of treatment and 12 weeks post treatment among subjects completing treatment and with HCV RNA less than the lower limit of quantification at the end of treatment", 
                "measure": "Percentage of subjects with post-treatment relapse", 
                "safety_issue": "No", 
                "time_frame": "Within 12 weeks post treatment"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}